PR inside: Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational ...
(PR-inside.com) Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter
Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million
EXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026
EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026
$26.3 million cash balance at June 30, 2026
Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time
DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu ..
https://reports.pr-inside.com/aytu-biop ... 226134.htm
Copyright PR-Inside.com 2026
